Do analysts rate JMAC or CRVS?

Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 155.04%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Corvus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings and valuation, JMAC or CRVS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is JMAC or CRVS more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Corvus Pharmaceuticals N/A -38.92% -35.75%

Which has preferable earnings & valuation, JMAC or CALT?

Maxpro Capital Acquisition has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A

Which has better valuation and earnings, COLL or JMAC?

Collegium Pharmaceutical has higher revenue and earnings than Maxpro Capital Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Collegium Pharmaceutical $796.33M 1.43 $62.87M $2.04 17.25 Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Do analysts rate SDGR or JMAC?

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 35.27%. Given Schrodinger's stronger consensus rating and higher possible upside, equities analysts clearly believe Schrodinger is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, SDGR or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than Schrodinger. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $254.91M 4.34 -$103.26M -$1.41 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Do analysts prefer MGTX or JMAC?

MeiraGTx currently has a consensus price target of $26.00, indicating a potential upside of 120.90%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, MGTX or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than MeiraGTx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $79.76M 13.67 -$114.20M -$1.48 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is MGTX or JMAC more profitable?

Maxpro Capital Acquisition has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% N/A -54.96% Maxpro Capital Acquisition N/A N/A N/A

Maxpro Capital Acquisition (JMAC) Competitors

$18.21 -0.65 (-3.45%)

As of 07/24/2026

Compare

JMAC vs. CRVS, CALT, COLL, SDGR, and MGTX

Should you buy Maxpro Capital Acquisition stock or one of its competitors? MarketBeat compares Maxpro Capital Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maxpro Capital Acquisition include Corvus Pharmaceuticals (CRVS), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Schrodinger (SDGR), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry.

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 0 mentions for Maxpro Capital Acquisition. Corvus Pharmaceuticals' average media sentiment score of 1.50 beat Maxpro Capital Acquisition's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Corvus Pharmaceuticals	Positive

Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 155.04%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maxpro Capital Acquisition's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Summary

Corvus Pharmaceuticals beats Maxpro Capital Acquisition on 7 of the 10 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Calliditas Therapeutics AB (publ)?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Calliditas Therapeutics AB (publ)'saverage media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Maxpro Capital Acquisition has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maxpro Capital Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Maxpro Capital Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

Maxpro Capital Acquisition beats Calliditas Therapeutics AB (publ) on 5 of the 7 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Collegium Pharmaceutical has higher revenue and earnings than Maxpro Capital Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.43	$62.87M	$2.04	17.25
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Maxpro Capital Acquisition's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Maxpro Capital Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Maxpro Capital Acquisition	N/A	N/A	N/A

In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 0 mentions for Maxpro Capital Acquisition. Collegium Pharmaceutical's average media sentiment score of 0.56 beat Maxpro Capital Acquisition's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Maxpro Capital Acquisition	Neutral

Collegium Pharmaceutical currently has a consensus target price of $57.50, suggesting a potential upside of 63.35%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, research analysts clearly believe Collegium Pharmaceutical is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Collegium Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Maxpro Capital Acquisition on 11 of the 13 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Maxpro Capital Acquisition has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Maxpro Capital Acquisition's return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Maxpro Capital Acquisition	N/A	N/A	N/A

Schrodinger has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

In the previous week, Schrodinger had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 3 mentions for Schrodinger and 0 mentions for Maxpro Capital Acquisition. Schrodinger's average media sentiment score of 1.26 beat Maxpro Capital Acquisition's score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.

Company	Overall Sentiment
Schrodinger	Positive
Maxpro Capital Acquisition	Neutral

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 35.27%. Given Schrodinger's stronger consensus rating and higher possible upside, equities analysts clearly believe Schrodinger is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Maxpro Capital Acquisition has lower revenue, but higher earnings than Schrodinger.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Schrodinger beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

MeiraGTx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Maxpro Capital Acquisition has lower revenue, but higher earnings than MeiraGTx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	13.67	-$114.20M	-$1.48	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

MeiraGTx currently has a consensus price target of $26.00, indicating a potential upside of 120.90%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, MeiraGTx had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for MeiraGTx and 0 mentions for Maxpro Capital Acquisition. MeiraGTx's average media sentiment score of 1.61 beat Maxpro Capital Acquisition's score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Overall Sentiment
MeiraGTx	Very Positive
Maxpro Capital Acquisition	Neutral

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Maxpro Capital Acquisition has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Maxpro Capital Acquisition	N/A	N/A	N/A

Summary

MeiraGTx beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JMAC vs. The Competition

Export

Metric	Maxpro Capital Acquisition	Holding Offices Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$244.52M	$248.44M	$7.24B	$12.26B
Dividend Yield	N/A	3.16%	40.99%	9.79%
P/E Ratio	N/A	6.11	23.62	23.64
Price / Sales	N/A	0.14	132.14	89.57
Price / Cash	N/A	267.85	165.01	59.64
Price / Book	N/A	27.96	12.77	6.07
Net Income	N/A	-$9.10M	$120.21M	$331.99M
7 Day Performance	-1.67%	-0.49%	-0.98%	-0.63%
1 Month Performance	-11.17%	7.67%	-2.00%	-2.00%
1 Year Performance	196.10%	8.04%	9.75%	13.62%

Maxpro Capital Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JMAC Maxpro Capital Acquisition	N/A	$18.21 -3.4%	N/A	+215.9%	$244.52M	N/A	N/A	2,021	Gap Down
CRVS Corvus Pharmaceuticals	2.9407 of 5 stars	$14.90 +4.4%	$33.33 +123.7%	+175.2%	$1.20B	N/A	N/A	30	News Coverage Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
COLL Collegium Pharmaceutical	3.0687 of 5 stars	$36.08 -0.5%	$57.50 +59.4%	+9.6%	$1.18B	$780.57M	17.69	210	News Coverage Analyst Downgrade
SDGR Schrodinger	2.3329 of 5 stars	$15.32 -1.8%	$20.25 +32.2%	-33.4%	$1.15B	$255.87M	N/A	790	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JMAC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. CRVS, CALT, COLL, SDGR, and MGTX

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Summary

How does Maxpro Capital Acquisition compare to Calliditas Therapeutics AB (publ)?

Summary

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Summary

How does Maxpro Capital Acquisition compare to Schrodinger?

Summary

How does Maxpro Capital Acquisition compare to MeiraGTx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. CRVS, CALT, COLL, SDGR, and MGTX

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Which has better earnings and valuation, JMAC or CRVS?

Which has more risk and volatility, JMAC or CRVS?

Does the media prefer JMAC or CRVS?

Do analysts rate JMAC or CRVS?

Do insiders and institutionals believe in JMAC or CRVS?

Is JMAC or CRVS more profitable?

Summary

How does Maxpro Capital Acquisition compare to Calliditas Therapeutics AB (publ)?

Does the media refer more to JMAC or CALT?

Which has preferable earnings & valuation, JMAC or CALT?

Do institutionals & insiders believe in JMAC or CALT?

Is JMAC or CALT more profitable?

Which has more risk and volatility, JMAC or CALT?

Summary

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Do insiders & institutionals hold more shares of COLL or JMAC?

Which has better valuation and earnings, COLL or JMAC?

Is COLL or JMAC more profitable?

Does the media refer more to COLL or JMAC?

Do analysts recommend COLL or JMAC?

Which has more risk & volatility, COLL or JMAC?

Summary

How does Maxpro Capital Acquisition compare to Schrodinger?

Do institutionals and insiders hold more shares of SDGR or JMAC?

Is SDGR or JMAC more profitable?

Which has more risk and volatility, SDGR or JMAC?

Does the media favor SDGR or JMAC?

Do analysts rate SDGR or JMAC?

Which has better earnings & valuation, SDGR or JMAC?

Summary

How does Maxpro Capital Acquisition compare to MeiraGTx?

Which has more volatility and risk, MGTX or JMAC?

Which has better earnings & valuation, MGTX or JMAC?

Do analysts prefer MGTX or JMAC?

Does the media favor MGTX or JMAC?

Do institutionals and insiders hold more shares of MGTX or JMAC?

Is MGTX or JMAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools